## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESM

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 December 31, Expires: 2014 Estimated average burden hours per

response

0.5

1. Name and Address of Reporting Person*	Requiring Statement (Month/Day/Year) 01/02/2015  WOLV 4. Re Issue	3. Issuer Name <b>and</b> Ticker or Trading Symbol WOLVERINE WORLD WIDE INC /DE/ [WWW]			
Gedra Ted S		4. Relationship of Reporting Person(s) to Issuer Filed (Month/Day/Year)			
(Last) (First) (Middle) C/O 9341 COURTLAND DRIVE NE		(Check all applicable)  Director  Other (specify below)  Director  Other (specify below)  Director  Other (specify below)  Director  Other (specify below)  Person  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person			
(Street) ROCKFORD MI 49351		President, Heritage Group  President, Heritage Group  Ferson  Form filed by More than One Reporting Person			
(City) (State) (Zip)					

Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)	2. Amount of Securities Owned (Instr. 4)		4. Nature of Indirect Beneficial Ownership (Instr. 5)					
Common Stock (1)	252,739	D						

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Excercise	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr.				
	Date Exercisable	Expiration Date	Title	Amount or Number of SharesM	Price of Derivative Security	or Indirect (I) (Instr. 5)	5)				
Stock Option (Right to Buy)	(2)	02/06/2017	Common Stock	23,600	\$ 15.13	D					
Stock Option (Right to Buy)	(3)	02/05/2018	Common Stock	32,000	\$ 12.53	D					
Stock Option (Right to Buy)	(4)	02/09/2019	Common Stock	42,000	\$ 8.56	D					
Stock Option (Right to Buy)	(5)	02/10/2020	Common Stock	30,400	\$ 12.5	D					
Stock Option (Right to Buy)	(6)	02/08/2021	Common Stock	20,800	\$ 18.25	D					
Stock Option (Right to Buy)	(7)	02/07/2022	Common Stock	22,400	\$ 19.92	D					
Stock Option (Right to Buy)	(8)	02/05/2023	Common Stock	25,240	\$ 21.48	D					
Stock Option (Right to Buy)	(9)	02/10/2024	Common Stock	22,123	\$ 27.13	D					

## **Explanation of Responses:**

- 1. The number of shares reported includes 16,796 restricted shares of common stock granted to the reporting person on February 11, 2014, under the Company's Stock Incentive Plan of 2013. Subject to the Company's achievement of specified performance criteria in accordance with the terms of the grant, restrictions on such shares will lapse in February 2017. In addition, the number of shares reported includes 18,492 and 20,584 restricted shares of common stock granted to the reporting person on February 8, 2012, and February 6, 2013, respectively, under the Company's Stock Incentive Plan of 2010. Subject to the Company's achievement of specified performance criteria in accordance with the terms of the grant, restrictions on 18,492 and 20,584 of such shares will lapse in February 2015 and February 2016, respectively. Any shares as to which restrictions do not lapse at such times will be forfeited.
- 2. This option became exercisable as to 7,867 shares on February 7, 2008, as to 7,867 shares on February 7, 2009, and as to 7,866 shares on February 7, 2010.
- 3. This option became exercisable as to 10,667 shares on February 6, 2009, as to 10,667 shares on February 6, 2010, and as to 10,666 shares on February 6, 2011.
- 4. This option became exercisable as to 14,000 shares on February 10, 2010, as to 14,000 shares on February 10, 2011, and as to 14,000 shares on February 10, 2012.
- 5. This option became exercisable as to 10,134 shares on February 10, 2011, as to 10,133 shares on February 10, 2012, and as to 10,133 shares on February 10, 2013.
- 6. This option became exercisable as to 6,934 shares on February 9, 2012, as to 6,933 shares on February 9, 2013, and as to 6,933 shares on February 9, 2014.
- 7. This option became exercisable as to 7,467 shares on February 8, 2013, and as to 7,466 shares on February 8, 2014, and becomes exercisable as to 7,467 shares on February 8, 2015.
- 8. This option became exercisable as to 8,414 shares on February 6, 2014, and becomes exercisable as to 8,413 shares on February 6, 2015, and as to 8,413 shares on February 6, 2016.
- 9. This option becomes exercisable as to 7,375 shares on February 10, 2015, as to 7,374 shares on February 10, 2016, and as to 7,374 shares on February 10, 2017.

/s/ Timothy E. Foley, by
Power of Attorney

\*\* Signature of Reporting

Date

Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned, a director and/or officer of Wolverine World Wide, Inc., a Delaware corporation ("Wolverine"), does hereby appoint BRENDAN M. GIBBONS and TIMOTHY E. FOLEY, or any one or more of them, with full power of substitution, his or her attorneys and agents to do any and all acts and things and to execute and file any and all documents and instruments that such attorneys and agents, or any of them, consider necessary or advisable to enable the undersigned (in his or her individual capacity or in a fiduciary or other capacity) to comply with the Securities Act of 1933, as amended (the "Securities Act"), and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any requirements of the Securities and Exchange Commission in respect thereof, in connection with his or her intended sale of any security related to Wolverine pursuant to Rule 144 issued under the Securities Act and the preparation, execution and filing of any report or statement of beneficial ownership or changes in beneficial ownership of securities of Wolverine that the undersigned (in his or her individual capacity or in a fiduciary or other capacity) may be required to file pursuant to Section 16(a) of the Exchange Act including, without limitation, full power and authority to sign the undersigned's name, in his or her individual capacity or in a fiduciary or other capacity, to any report or statement on Form 3, 4, 5 or 144, or to any amendments or any successor forms thereto, or any form or forms adopted by the Securities and Exchange Commission in lieu thereof or in addition thereto, hereby ratifying and confirming all that such attorneys and agents, or any of them, shall do or cause to be done by virtue hereof.

The undersigned agrees that the attorneys-in-fact act as legal counsel to and/or officers of Wolverine in connection with the securities matters addressed herein, and do not represent the undersigned in his or her personal capacity in connection with such matters. The undersigned agrees that the attorneys-in-fact may rely entirely on information furnished orally or in writing by the undersigned or his or her authorized representative(s) to such attorneys-in-fact. The undersigned also agrees to indemnify and hold harmless Wolverine and the attorneys-in-fact against any losses, claims, damages or liabilities (or actions in respect thereof) that arise out of or are based upon any untrue statement or omission of necessary fact in the information provided by the undersigned or his or her authorized representative(s) to the attorneys-in-fact for purposes of executing, acknowledging, delivering or filing any such forms, or any amendments or any successor forms thereto, or any form or forms adopted by the Securities and Exchange Commission in lieu thereof or in addition thereto. The undersigned agrees to reimburse Wolverine and the attorneys-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This authorization shall supersede all prior authorizations to act for the undersigned with respect to securities of Wolverine in these matters, which prior authorizations are hereby revoked, and shall survive the termination of the undersigned's status as a director and/or officer of Wolverine and remain in effect thereafter for so long as the undersigned (in his or her individual capacity or in a fiduciary or other capacity) is subject to Rule 144 with respect to securities of Wolverine or has any obligation under Section 16 of the Exchange Act with respect to securities of Wolverine.

Date: January 7, 2015

/s/ Ted S. Gedra
(Signature)

Ted S. Gedra (Name)